
About Sensible Biotechnologies
Sensible Biotechnologies is a Healthcare company based in Wilmington (United States) founded in 2021 by Miroslav Gasparek. Developer of mRNA technology for therapeutics and vaccines. Sensible Biotechnologies has raised $51.33 million across 3 funding rounds from investors including BlueYard Capital, Y Combinator and Amino Collective. Its chief executive, as recorded, is Miroslav Gasparek. Sensible Biotechnologies offers products and services including mRNA Manufacturing Platform and In Vivo Microbial mRNA System. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Research Reagents and Kits and Genomics. Its legal entity is Sensible Biotechnologies, Inc. Its competitors include Twist Bioscience, Parse Biosciences and Ansa Biotechnologies; 3 of its 3 listed competitors have raised funding.
Company details
Sensible Biotechnologies was founded in 2021 and is headquartered in Wilmington, United States. Focus is placed on the biotechnology sector, where mRNA technology is designed and manufactured for therapeutics and vaccines. Principles of cell engineering, computational biology, and precision fermentation are integrated into operations to enable efficient production. Leadership is provided by co-founder and CEO Miroslav Gasparek, with activities centered on advancing mRNA applications in healthcare.
- Headquarters Wilmington, United States
- Founders Miroslav Gasparek
- SectorsHealthcare
- Emailβ’β’β’β’β’β’β’β’
- Phoneβ’β’β’β’ β’β’β’β’
- Website sensible.bio
- Social LinkedIn X Facebook
- Legal Name Sensible Biotechnologies, Inc.
- Total Equity Funding$51.33M (USD)
in 3 rounds
- Latest Funding Round$47M (USD), Series A
Oct 2026
- InvestorsBlueYard Capital
& 13 more
Products & Services of Sensible Biotechnologies
Sensible Biotechnologies offers a comprehensive portfolio of products and services, including mRNA Manufacturing Platform and In Vivo Microbial mRNA System.
Produces pure mRNA for therapeutics and vaccines efficiently.
Enables scalable mRNA production for global health applications.
Funding Insights of Sensible Biotechnologies
Sensible Biotechnologies has successfully raised a total of $51.33M across 3 strategic funding rounds. The most recent funding activity was a Series A round of $47 million completed in October 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $51.33M
- Total Rounds 3
- Last Round Series A β $47M
- First Round $125,000
(Jun 2021)
- Investors Count 14
All 3 funding rounds of Sensible Biotechnologies with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2026 | $47M | Series A | β | β | |
| Feb 2023 | $4.2M | Seed | β | BlueYard | |
| Jun 2021 | $125,000 | Seed | β | Y Combinator | β |
14 investors in total: 12 institutional and 2 angel.
Investors in Sensible Biotechnologies
Sensible Biotechnologies has secured backing from 14 investors, including venture fund and angel investors. Prominent investors backing the company include BlueYard Capital, Y Combinator and Amino Collective.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
BlueYard Capital is engaged in early-stage technology investments. | 2016 | blueyard.com | United States | |
Early-stage startups are accelerated via funding and educational programs. | ycombinator.com | Mountain View, United States | ||
Amino Collective is engaged in backing innovative startup founders. | aminocollective.com | |||
Venture capital is provided to health tech and biology innovations. | civilizationventures.com | San Francisco, United States | ||
Recode Ventures is focused on healthcare and deep tech investments. | recodehealth.vc | San Francisco, United States | ||
ZAKA VC is focused on seed and pre-seed investments. | zaka.vc | Prague, Czechia | ||
| otb.vc | ||||
| iqt.org | ||||
| recodeventures.com | ||||
| isomercapital.com |
Investor details for Sensible Biotechnologies
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Sensible Biotechnologies
1 people are tracked at Sensible Biotechnologies (1 in leadership).
| Name | Role | Group |
|---|---|---|
Miroslav Gasparek | Co-Founder & CEO | Leadership |
Complete people profiles for Sensible Biotechnologies
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Sensible Biotechnologies
3 dated milestones of Sensible Biotechnologies across 5 years, from founding to its latest funding, stage changes and deals.
- Founded Sensible Biotechnologies is founded.
- Funding First funding round of $125K.
- Funding Latest funding round, Series A, of $47.0M.
Competitors of Sensible Biotechnologies
Sensible Biotechnologies has 3 listed competitors in our database, 3 of them funded. They include Twist Bioscience, Parse Biosciences and Ansa Biotechnologies.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| twistbioscience.com | 2013 | San Francisco, United States | $245.81M | 919 | Synthetic DNA is synthesized via a semiconductor-based platform. | |
| parsebiosciences.com | 2018 | Seattle, United States | $100.26M | RNA-sequencing transcriptome kits for health data analysis are developed. | ||
| ansabio.com | 2017 | Berkeley, United States | $175.5M | 253 | DNA synthesis technology using enzymes is provided. |
Detailed competitors of Sensible Biotechnologies
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Sensible Biotechnologies
The website of Sensible Biotechnologies (sensible.bio) receives about 2.2K visits a month.
- Monthly visits2.2K
▼ 52.1% vs previous month
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Sensible Biotechnologies (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Sensible Biotechnologies
Complete news archive for Sensible Biotechnologies
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Sensible Biotechnologies
Sensible Biotechnologies was founded in 2021.
Sensible Biotechnologies is headquartered in Wilmington, United States. It is registered at Wilmington, Delaware, United States.
Miroslav Gasparek is the CEO of Sensible Biotechnologies, as recorded in our data. They have also founded this company.
Sensible Biotechnologies is a funded company, having raised a total of $51.33M across 3 funding rounds to date. The company's 1st funding round was a Seed of $125K, raised on Jun 2021.
Sensible Biotechnologies was founded in 2021 and is headquartered in Wilmington, United States. Focus is placed on the biotechnology sector, where mRNA technology is designed and manufactured for therapeutics and vaccines. Principles of cell engineering, computational biology, and precision fermentation are integrated into operations to enable efficient production. Leadership is provided by co-founder and CEO Miroslav Gasparek, with activities centered on advancing mRNA applications in healthcare.
Sensible Biotechnologies's top competitors include Parse Biosciences, Twist Bioscience and Ansa Biotechnologies.
Sensible Biotechnologies offers mRNA Manufacturing Platform and In Vivo Microbial mRNA System.
Sensible Biotechnologies has 14 investors. Key investors include BlueYard Capital, Y Combinator, Amino Collective, Civilization Ventures, and Recode Ventures.
Sensible Biotechnologies operates through Sensible Biotechnologies, Inc..
